Bristol Myers Squibb Receives European Commission Approval for Inrebic® (fedratinib) for Adult Patients with Newly Diagnosed and Previously Treated Myelofibrosis
Go back to Bristol Myers Squibb Receives European Commission Approval for Inrebic® (fedratinib) for Adult Patients with Newly Diagnosed and Previously Treated Myelofibrosis| Bristol-Myers Squibb (NYSE: BMY) | Delayed: 64.50 -0.19 (0.29%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $64.69 | 52 Week High | $77.12 | |||
| Open | $64.57 | 52 Week Low | $49.03 | |||
| Day High | $65.05 | P/E | 41.88 | |||
| Day Low | $64.29 | EPS | $1.54 | |||
| Volume | 2,016,527 | |||||
